Opens in a new tab

Breaking news

Greenland’s Tourism Boom: Trump Effect And New Airports Drive Growth

Greenland is witnessing a surge in tourism, fueled by renewed international attention following remarks by former U.S. President Donald Trump and a wave of new infrastructure projects. The opening of Nuuk’s new international airport has significantly improved access, with direct flights from New York set to begin in June.

Key Facts

  • 14% rise in international arrivals: Statistics Greenland reported a sharp increase in January year-on-year.
  • Hotel stays surged: 355,000 nights recorded last year, up from 210,000 in 2014.
  • Nuuk Airport opened in November, streamlining travel and bypassing layovers in Copenhagen and Kangerlussuaq.
  • Ilulissat and Qaqortoq to get international airports, further boosting accessibility.
  • Three-quarters of tour operators saw increased bookings after Nuuk Airport’s opening.

The Bigger Picture

Greenland’s tourism momentum comes amid U.S. interest in the Arctic island’s rare earth minerals, critical for high-tech industries. While Trump’s idea of acquiring Greenland sparked controversy, it undeniably placed the region in the global spotlight. The country now aims to diversify its economy—currently 95% dependent on fishing—by leveraging tourism and mining.

With breathtaking glaciers, deep fjords, and a rich Inuit cultural heritage, Greenland’s tourism industry is poised for unprecedented growth.

Isomorphic Labs Raises $5 Billion To Advance AI-Designed Medicines

Isomorphic Labs, the AI drug discovery company founded by Demis Hassabis, has raised $5 billion in a Series C funding round, highlighting growing investor confidence in artificial intelligence’s potential to transform pharmaceutical research.

The round was co-led by Greenoaks and Sequoia Capital, with participation from Andreessen Horowitz and Alphabet, Google’s parent company. Isomorphic said the funding will support the design and development of new medicines using AI.

Hassabis Focuses On The Next Phase Of Isomorphic Labs

The fundraising comes three and a half months after Hassabis stepped back as CEO of Google DeepMind, the AI research lab he co-founded before its acquisition by Google in 2014. He has led Isomorphic Labs since it spun out of DeepMind in 2021.

“When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI,” Hassabis said.

He added that the new capital would help the company develop foundational biology models, deepen its understanding of systemic disease and advance its first therapeutic programmes towards clinical trials.

AI Drug Discovery Attracts Growing Investment

Isomorphic is developing a proprietary drug-design engine alongside a pipeline of potential therapies designed using AI. The company aims to apply these tools to the development of a new generation of medicines.

It is entering a market that is attracting increasing attention from technology companies and investors. Anthropic announced an AI drug discovery programme in June, while OpenAI partnered with Novo Nordisk in April to explore the technology’s applications in drug development.

Drug discovery startups raised a record $23.2 billion in 2026, according to deal-tracking platform Dealroom.

Isomorphic’s latest funding follows a $2.1 billion Series B round announced in May, bringing the company’s fundraising into focus as investment in AI-driven pharmaceutical research continues to grow.

eCredo
The Future Forbes Realty Global Properties
Uol
Aretilaw firm

Become a Speaker

Become a Speaker

Become a Partner

Subscribe for our weekly newsletter